Literature DB >> 7671246

Carcinogenic activities of various steroidal and nonsteroidal estrogens in the hamster kidney: relation to hormonal activity and cell proliferation.

J J Li1, S A Li, T D Oberley, J A Parsons.   

Abstract

The therapeutic use of estrogens has been associated with an increased risk of some of the most predominant, as well as less prevalent, cancers in women. The estrogen-induced renal tumor is one of the primary animal models to evaluate the carcinogenic properties of estrogens. Correlations were made with various estrogens by using parameters of estrogenicity end points such as competitive binding, progesterone receptor induction, and alterations in prolactin levels; in vitro renal proximal cell proliferation; and in vivo estrogen-induced carcinogenicity. The most potent estrogens were Moxestrol (MOX), diethylstilbestrol (DES), and 17 beta-estradiol, followed by indenestrol B, 16 alpha-hydroxyestrone, and 11 beta-methoxyestradiol with moderate estrogenic activities, whereas 11 beta-methylestradiol, 17 alpha-estradiol, indanestrol, and deoxoestrone were all relatively weaker. As expected, hydrolyzed Premarin (unconjugated estrogens) was strongly estrogenic. Of the estrogens tested, MOX was the most potent carcinogenic estrogen in the hamster kidney. Both 16 alpha-hydroxyestrone and 11 beta-methoxyestradiol induced intermediate tumor incidences with distinctly lower frequencies of renal tumor foci compared to the most potent carcinogenic estrogens. However, hamsters treated for 9.0 months with 11 beta-methylestradiol, 17 alpha-estradiol, deoxoestrone, and indanestrol exhibited no tumors. In contrast, treatment with estrone, equilin plus d-equilenin, and hydrolyzed Premarin for the same time period resulted in 100% renal tumor incidences and numerous tumor foci. Cell proliferation studies of cultured hamster kidney proximal tubule cells were carried out at varying estrogen concentrations (0.01-100 nM). Exposure to MOX resulted in consistently high renal cell proliferative response over a concentration range of 0.1-10 nM. Strongly carcinogenic estrogens such as estrone had a maximal renal cell proliferation response (2.4-fold above untreated control levels) between 0.1 and 10 nM, DES and 17 beta-estradiol responded at 1.0 nM, and 4-hydroxyestradiol responded at 10 nM. Interestingly, exposure to ethinylestradiol, a potent estrogen, at similar or higher doses as those used for DES and 17 beta-estradiol, yielded only a 10% renal tumor incidence and induced only a 1.7-fold increase in proximal tubule cell proliferation. In contrast, 17 alpha-estradiol, deoxoestrone, indanestrol, and 11 beta-methylestradiol, all weakly estrogenic and noncarcinogenic agents, had relatively little effect on tubule cell proliferation. The hydrolyzed Premarin exhibited a maximal 2.0-fold cell proliferative response at 10 nM. The present results provide clear evidence that, in the hamster kidney, the degree of carcinogenicity of a given estrogen correlates with its ability to induce proximal tubule cell proliferation in vitro.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7671246

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  Detection of estrogen DNA-adducts in human breast tumor tissue and healthy tissue by combined nano LC-nano ES tandem mass spectrometry.

Authors:  J Embrechts; F Lemière; W Van Dongen; E L Esmans; P Buytaert; E Van Marck; M Kockx; A Makar
Journal:  J Am Soc Mass Spectrom       Date:  2003-05       Impact factor: 3.109

2.  Inhibition of aberrant androgen receptor induction of prostate specific antigen gene expression, cell proliferation and tumor growth by 17α-estradiol in prostate cancer.

Authors:  Yaming Qiao; Lu Wang; Li-Qun Cai; Chen Tan; Julianne Imperato-McGinley; Yuan-Shan Zhu
Journal:  J Urol       Date:  2011-01       Impact factor: 7.450

3.  Redox cycling of catechol estrogens generating apurinic/apyrimidinic sites and 8-oxo-deoxyguanosine via reactive oxygen species differentiates equine and human estrogens.

Authors:  Zhican Wang; Esala R Chandrasena; Yang Yuan; Kuan-wei Peng; Richard B van Breemen; Gregory R J Thatcher; Judy L Bolton
Journal:  Chem Res Toxicol       Date:  2010-08-16       Impact factor: 3.739

Review 4.  The role of estrogen in the initiation of breast cancer.

Authors:  J Russo; Irma H Russo
Journal:  J Steroid Biochem Mol Biol       Date:  2006-12       Impact factor: 4.292

5.  Translesion synthesis past equine estrogen-derived 2'-deoxyadenosine DNA adducts by human DNA polymerases eta and kappa.

Authors:  Manabu Yasui; Y R Santosh Laxmi; Sreenivasa R Ananthoju; Naomi Suzuki; Sung Yeon Kim; Shinya Shibutani
Journal:  Biochemistry       Date:  2006-05-16       Impact factor: 3.162

6.  Unexpected hormonal activity of a catechol equine estrogen metabolite reveals reversible glutathione conjugation.

Authors:  Kuan-Wei Peng; Minsun Chang; Yue-Ting Wang; Zhican Wang; Zhihui Qin; Judy L Bolton; Gregory R J Thatcher
Journal:  Chem Res Toxicol       Date:  2010-08-16       Impact factor: 3.739

7.  17alpha-estradiol inhibits LAPC-4 prostatic tumor cell proliferation in cell cultures and tumor growth in xenograft animals.

Authors:  Yaming Qiao; Zhi-Kai Zhang; Li-Qun Cai; Chen Tan; Julianne L Imperato-McGinley; Yuan-Shan Zhu
Journal:  Prostate       Date:  2007-12-01       Impact factor: 4.104

8.  Selective estrogen receptor modulator delivery of quinone warheads to DNA triggering apoptosis in breast cancer cells.

Authors:  Kuan-Wei Peng; Huali Wang; Zhihui Qin; Gihani T Wijewickrama; Meiling Lu; Zhican Wang; Judy L Bolton; Gregory R J Thatcher
Journal:  ACS Chem Biol       Date:  2009-12-18       Impact factor: 5.100

9.  Quantitative detection of 4-hydroxyequilenin-DNA adducts in mammalian cells using an immunoassay with a novel monoclonal antibody.

Authors:  Yumiko Okahashi; Takaaki Iwamoto; Naomi Suzuki; Shinya Shibutani; Shigeki Sugiura; Shinji Itoh; Tomohisa Nishiwaki; Satoshi Ueno; Toshio Mori
Journal:  Nucleic Acids Res       Date:  2010-04-20       Impact factor: 16.971

10.  Equine estrogen-induced mammary tumors in rats.

Authors:  Yoshinori Okamoto; Xiaoping Liu; Naomi Suzuki; Kanako Okamoto; Hyo Jeong Kim; Y R Santosh Laxmi; Kazutoshi Sayama; Shinya Shibutani
Journal:  Toxicol Lett       Date:  2010-01-22       Impact factor: 4.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.